Jane Huang - 04 Jul 2025 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
President, CMO
Signature
/s/ Bryant D. Lim, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
04 Jul 2025
Net transactions value
-$2,664
Form type
4
Filing time
08 Jul 2025, 16:06:56 UTC
Previous filing
13 Jun 2025
Next filing
07 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Huang Jane President, CMO C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON /s/ Bryant D. Lim, Attorney-in-Fact 08 Jul 2025 0001683913

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise +9,375 +13% 84,252 04 Jul 2025 Direct F1
transaction PRLD Common Stock Tax liability $2,664 -3,355 -4% $0.7939 80,897 04 Jul 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Restricted Stock Unit Options Exercise $0 -9,375 -25% $0.000000 28,125 04 Jul 2025 Common Stock 9,375 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2 Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
F3 The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.